KRAS and acute myeloid leukemia: In approximately two-thirds of AML cases, signaling and kinase pathway gene mutations (e.g., FLT3, KRAS, NRAS, PTPN11, NF1, and KIT) are the most common mutational subset in AML, causing atypical activation of cellular signaling pathways [7].